The Drug Discovery Services Market is expected to grow from USD 10.91 billion in 2019 to USD 23.55 billion by 2026 at a CAGR of 12.02% from 2020 to 2026.
Drug discovery services have suffered a drastic change with the improvements in current molecular biology methods and advanced knowledge of the human genome. It is becoming a more hypothesis-driven target-based method. Pharmaceutical companies and regulatory bodies are causative to drug discovery. These services are an effective way of guide, transport a drug discovery platform in the field of biotechnology and pharmacology. Furthermore, these services are subcontracting is a complex, lengthy, expensive process and the duration for drug discovery is very high. The process of drug discovery contains docking molecular, drug target identification, drug discovery screening, small molecule screening, library screening, ion channel screening, etc. Maximum pharmaceutical use of these services during the clinical inspection or final stages of drug discovery so as to concentrate on other competencies of drug-like marketing, product structuring, process management, and manufacturing. The global market is segregated on the basis of Type as Drug Metabolism and Pharmacokinetics, Small- molecule Drugs, Biologic Drugs, Medicinal Chemistry Services, and Biology Services. Based on Therapeutic Area the global market is segmented in Digestive System Diseases, Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, and Infectious and Immune System Diseases. Based on Company Type the global market is segmented in Tier 3 Pharmaceutical Companies, Tier 2 Pharmaceutical Companies, and Tier 1 Pharmaceutical Companies. Based on Process, the global market is segmented in Hit-To-Lead Identification, Lead Optimization, Candidate Validation, Target Selection, and Target Validation.
The global Drug Discovery Services market report provides geographical analysis covering regions, such as Europe, North America, Asia Pacific, and the Rest of The World. The market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.
Competitive Rivalry
Jubilant Lifesciences, Genscript Biotech Corporation, Piramal Enterprises Limited, Selvita S.A., Aurigene Discovery Technologies, Laboratory Corporation of America Holdings, Eurofins Scientific Se, Charles River Laboratories International, Evotec SE, Thermo Fisher Scientific, and others are among the major players in the global market. The companies studied in terms of product strategy and various n several growths and expansion strategies to gain a competitive edge in the market. The major players not only follow value chain integration with business operations in multiple stages of the value chain.
The global Drug Discovery Services market has been segmented as below:
By Type
By Therapeutic Area
By Company Type
By Process
By Region
By Company
The report covers the below scope:
The years considered for the study are as follows:
Report Scope:
The global Drug Discovery Services market report scope includes a detailed study covering underlying factors influencing the industry trends. The report covers the analysis of regional and country-level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies. The report scope includes a detailed competitive outlook covering market shares and profiles key participants in the global market share. Major industry players with significant revenue share include Jubilant Lifesciences, Genscript Biotech Corporation, Piramal Enterprises Limited, Selvita S.A., Aurigene Discovery Technologies, Laboratory Corporation of America Holdings, Eurofins Scientific Se, Charles River Laboratories International, Evotec SE, Thermo Fisher Scientific, and others.
Why to Buy this Report:
Target Audience:
The report targeted the existing players in the industry is as follows:
Free and Paid Customization based on the requirement
Report Content
1.1 Key Insights
1.2 Report Overview
1.3 Markets Covered
1.4 Stakeholders
2.1 Research Scope
2.2 Market Research Process
2.3 Research Data Analysis
2.4.1 Secondary Research
2.4.2 Primary Research
2.4.3 Models for Estimation
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach - Segmental Market Analysis
2.5.2 Top-Down Approach - Parent Market Analysis
4.1 Introduction
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.2 Porter's Five Force Analysis
5.1 Introduction
5.2 Drug Metabolism and Pharmacokinetics
5.2.1 Market Overview
5.2.2 Market Size and Forecast
5.3 Small- molecule Drugs
5.3.1 Market Overview
5.3.2 Market Size and Forecast
5.4 Biologic Drugs
5.4.1 Market Overview
5.4.2 Market Size and Forecast
5.5 Medicinal Chemistry Services
5.5.1 Market Overview
5.5.2 Market Size and Forecast
5.6 Biology Services
5.6.1 Market Overview
5.6.2 Market Size and Forecast
6.1 Introduction
6.2 Digestive System Diseases
6.2.1 Market Overview
6.2.2 Market Size and Forecast
6.3 Cardiovascular Diseases
6.3.1 Market Overview
6.3.2 Market Size and Forecast
6.4 Other Therapeutic Areas
6.4.1 Market Overview
6.4.2 Market Size and Forecast
6.5 Oncology
6.5.1 Market Overview
6.5.2 Market Size and Forecast
6.6 Neurology
6.6.1 Market Overview
6.6.2 Market Size and Forecast
6.7 Infectious and Immune System Diseases
6.7.1 Market Overview
6.7.2 Market Size and Forecast
7.1 Introduction
7.2 Tier 3 Pharmaceutical Companies
7.2.1 Market Overview
7.2.2 Market Size and Forecast
7.3 Tier 2 Pharmaceutical Companies
7.3.1 Market Overview
7.3.2 Market Size and Forecast
7.4 Tier 1 Pharmaceutical Companies
7.4.1 Market Overview
7.4.2 Market Size and Forecast
8.1 Introduction
8.2 Hit-To-Lead Identification
8.2.1 Market Overview
8.2.2 Market Size and Forecast
8.3 Lead Optimization
8.3.1 Market Overview
8.3.2 Market Size and Forecast
8.4 Candidate Validation
8.4.1 Market Overview
8.4.2 Market Size and Forecast
8.5 Target Selection
8.5.1 Market Overview
8.5.2 Market Size and Forecast
8.6 Target Validation
8.6.1 Market Overview
8.6.2 Market Size and Forecast
9.1 Introduction
9.2 Europe
9.2.1 Europe Market, By Type
9.2.2 Europe Market, By Therapeutic Area
9.2.3 Europe Market, By Company Type
9.2.4 Europe Market, By Process
9.3 North America
9.3.1 North America Market, By Type
9.3.2 North America Market, By Therapeutic Area
9.3.3 North America Market, By Company Type
9.3.4 North America Market, By Process
9.4 Asia Pacific
9.4.1 Asia Pacific Market, By Type
9.4.2 Asia Pacific Market, By Therapeutic Area
9.4.3 Asia Pacific Market, By Company Type
9.4.4 Asia Pacific Market, By Process
9.5 Rest of The World
9.5.1 Rest of The World Market, By Type
9.5.2 Rest of The World Market, By Therapeutic Area
9.5.3 Rest of The World Market, By Company Type
9.5.4 Rest of The World Market, By Process
10.1 Key Insights
10.2 Company Market Share Analysis
10.3 Strategic Outlook
10.3.1 Mergers & Acquisitions
10.3.2 New Product Development
10.3.3 Portfolio/Production Capacity Expansions
10.3.4 Joint Ventures, Collaborations, Partnerships & Agreements
10.3.5 Others
11.1 Jubilant Lifesciences
11.1.1 Company Overview
11.1.2 Product/Service Landscape
11.1.3 Financial Overview
11.1.4 Recent Developments
11.2 Genscript Biotech Corporation
11.2.1 Company Overview
11.2.2 Product/Service Landscape
11.2.3 Financial Overview
11.2.4 Recent Developments
11.3 Piramal Enterprises Limited
11.3.1 Company Overview
11.3.2 Product/Service Landscape
11.3.3 Financial Overview
11.3.4 Recent Developments
11.4 Selvita S.A.
11.4.1 Company Overview
11.4.2 Product/Service Landscape
11.4.3 Financial Overview
11.4.4 Recent Developments
11.5 Aurigene Discovery Technologies
11.5.1 Company Overview
11.5.2 Product/Service Landscape
&a
By Type
By Therapeutic Area
By Company Type
By Process